CD4 mimetic miniproteins: potent anti-HIV compounds with promising activity as microbicides.
about
Conformational Masking and Receptor-Dependent Unmasking of Highly Conserved Env Epitopes Recognized by Non-Neutralizing Antibodies That Mediate Potent ADCC against HIV-1Microbicides: topical prevention against HIVMiniCD4 microbicide prevents HIV infection of human mucosal explants and vaginal transmission of SHIV(162P3) in cynomolgus macaquesCombinatorial Optimization of a CD4-Mimetic Miniprotein and Cocrystal Structures with HIV-1 gp120 Envelope GlycoproteinStructural Basis for Highly Effective HIV-1 Neutralization by CD4-Mimetic Miniproteins Revealed by 1.5 Å Cocrystal Structure of gp120 and M48U1Interfacial Cavity Filling To Optimize CD4–Mimetic Miniprotein Interactions with HIV-1 Surface GlycoproteinHeavy Chain-Only IgG2b Llama Antibody Effects Near-Pan HIV-1 Neutralization by Recognizing a CD4-Induced Epitope That Includes Elements of Coreceptor- and CD4-Binding SitesCrystal Structures of HIV-1 gp120 Envelope Glycoprotein in Complex with NBD Analogues That Target the CD4-Binding SiteMonocytes contribute to differential immune pressure on R5 versus X4 HIV through the adipocytokine visfatin/NAMPTElicitation of neutralizing antibodies directed against CD4-induced epitope(s) using a CD4 mimetic cross-linked to a HIV-1 envelope glycoproteinQuaternary structures of HIV Env immunogen exhibit conformational vicissitudes and interface diminution elicited by ligand bindingStructure-based identification and neutralization mechanism of tyrosine sulfate mimetics that inhibit HIV-1 entry.The N276 glycosylation site is required for HIV-1 neutralization by the CD4 binding site specific HJ16 monoclonal antibody.Stabilization of HIV-1 envelope in the CD4-bound conformation through specific cross-linking of a CD4 mimeticThermosensitive and mucoadhesive pluronic-hydroxypropylmethylcellulose hydrogel containing the mini-CD4 M48U1 is a promising efficient barrier against HIV diffusion through macaque cervicovaginal mucusCD4 mimetics sensitize HIV-1-infected cells to ADCC.In vitro activities of candidate microbicides against cell-associated HIVFunctional Mimetics of the HIV-1 CCR5 Co-Receptor Displayed on the Surface of Magnetic Liposomes.Cocrystal Structures of Antibody N60-i3 and Antibody JR4 in Complex with gp120 Define More Cluster A Epitopes Involved in Effective Antibody-Dependent Effector Function against HIV-1MiniCD4 protein resistance mutations affect binding to the HIV-1 gp120 CD4 binding site and decrease entry efficiency.Straightforward selection of broadly neutralizing single-domain antibodies targeting the conserved CD4 and coreceptor binding sites of HIV-1 gp120M48U1 CD4 mimetic has a sustained inhibitory effect on cell-associated HIV-1 by attenuating virion infectivity through gp120 shedding.Synergism between a CD4-mimic peptide and antibodies elicited by a constrained V3 peptide.Scorpion peptides: potential use for new drug developmentBlocking HIV-1 gp120 at the Phe43 cavity: if the extension fits…Small-molecule CD4 mimics interact with a highly conserved pocket on HIV-1 gp120.A simple one-step method for the preparation of HIV-1 envelope glycoprotein immunogens based on a CD4 mimic peptide.Co-receptor Binding Site Antibodies Enable CD4-Mimetics to Expose Conserved Anti-cluster A ADCC Epitopes on HIV-1 Envelope Glycoproteins.M48U1 and Tenofovir combination synergistically inhibits HIV infection in activated PBMCs and human cervicovaginal histocultures.HIV sexual transmission and microbicides.Protein/peptide-based entry/fusion inhibitors as anti-HIV therapies: challenges and future direction.Increased, durable B-cell and ADCC Responses Associated with T-helper Responses to HIV-1 Envelope in Macaques Vaccinated with gp140 Occluded at the CD4 Receptor Binding Site.Crosslinking of a CD4 Mimetic Miniprotein with HIV-1 Env gp140 Alters Kinetics and Specificities of Antibody Responses against HIV-1 Env in Macaques.Trimeric HIV Env provides epitope occlusion mediated by hypervariable loopsMimicking the structure of the V3 epitope bound to HIV-1 neutralizing antibodiesTargeting the Late Stage of HIV-1 Entry for Antibody-Dependent Cellular Cytotoxicity: Structural Basis for Env Epitopes in the C11 Region.An update of the recombinant protein expression systems of Cyanovirin-N and challenges of preclinical development.Amino acid derivatives. Part 6. Synthesis, in vitro antiviral activity and molecular docking study of new N-α-amino acid derivatives conjugated spacer phthalimide backbone
P2860
Q26782237-86CEAB92-D923-4FBB-BA88-A0DB2409CB30Q26999403-5D81E56C-BECE-4C62-9583-8074F92376E0Q27339377-F618E9EB-6F7F-49F8-8D36-91B29BB26C1BQ27651139-487B9DE9-4BC9-4D9E-81CB-76BD1C5B4996Q27678297-79BECB5F-445C-4368-896F-1ECF5057A8ECQ27678341-1C872B74-DF36-4F74-8912-770F9A4E781DQ27679031-D37F06BE-B6A6-46A5-A806-5B616553F4D2Q27681568-D64A700B-6E04-4921-8DAC-1F23A7A44ABCQ28730721-6F833C87-3D78-4B81-8A3D-8B91410E716FQ28732438-9BC6ED23-B8AA-4122-A1FF-D55D251A6A98Q30499590-E8BDC7ED-1CC0-4D50-AAF6-5F27D31AB854Q33972838-E55B47B7-B222-44CD-9A1C-ACB65C8B088EQ34851484-F4600F34-E096-43A3-9F42-AFA77500511BQ35065249-1BDFE604-DE00-4D57-BEA2-68922914A304Q35169031-2342DA8E-3CC3-49EF-A0C7-083FF24219EEQ35644696-232009CF-B9FA-4EA0-8FAD-CE5ACBD1ED14Q35689194-C87B1E84-2821-443B-A5DC-35864367750FQ35858649-EBCFCDD6-0000-4E2A-B99B-9F29D284CEF1Q35913921-A84CE8AE-AB12-4A4E-B417-778AE9769605Q36127736-0A7275F6-A7EC-47A0-9277-38DBD18608F0Q36559665-41ABEF83-0F05-4EB0-BFA8-61136842E9E8Q36608485-6CC5C3FB-047B-4F3E-8EF1-08542D1F4E3BQ36715717-048B7301-CB84-48C5-8C2E-C4AF42C10658Q36971525-5151C858-3735-40B6-BA0D-463FED6B4A65Q36983858-759429FA-AFD4-456D-8551-165D1A0DED9EQ37002237-296DAF4C-B2EB-429E-96C3-B3E2E326908CQ37102810-703B2FEB-86F4-4880-8AE6-C33A09577FC4Q37363561-98417EF2-1F7E-4BDB-9240-E8F071919799Q37618276-650FA9BB-A2A5-4C46-AD27-EA2C7218D7EAQ37853935-7A19AC44-410B-46A9-879B-FBDBAEC2C50EQ38574172-A06EC004-03FD-42D4-BF82-98C37ED4FBD9Q38658529-B4005722-3719-4C31-A626-8070AC41EB00Q38793711-1163EEB8-7409-4108-956C-D199F9B00B52Q42181481-7C80AFD6-33E1-4A0F-BEA6-69A624E1162CQ42576275-DA46CF77-708D-47AC-992C-5DEA21D889C8Q47604797-B3381CEB-AA9E-466B-AD4A-4CB8CD8E45D2Q55516259-458EA007-9E49-4E82-9FB7-663BE4FC7A59Q57269135-1F3D9249-F185-4C61-9ADA-5277A4694CB1
P2860
CD4 mimetic miniproteins: potent anti-HIV compounds with promising activity as microbicides.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
CD4 mimetic miniproteins: pote ...... sing activity as microbicides.
@en
CD4 mimetic miniproteins: pote ...... sing activity as microbicides.
@nl
type
label
CD4 mimetic miniproteins: pote ...... sing activity as microbicides.
@en
CD4 mimetic miniproteins: pote ...... sing activity as microbicides.
@nl
prefLabel
CD4 mimetic miniproteins: pote ...... sing activity as microbicides.
@en
CD4 mimetic miniproteins: pote ...... sing activity as microbicides.
@nl
P2093
P356
P1476
CD4 mimetic miniproteins: pote ...... sing activity as microbicides.
@en
P2093
Anne Descours
Guido Vanham
Jo Michiels
Laetitia Aerts
Laurence Morellato
Leo Heyndrickx
Loïc Martin
Yven Van Herrewege
P304
P356
10.1093/JAC/DKN042
P407
P577
2008-02-12T00:00:00Z